ArticleMolecular diversity2026
Palladium-catalyzed borylative coupling of hypervalent iodine diazo reagents with boranes for the synthesis of organoboron carboxylate.
Article in Molecular diversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
A palladium-catalyzed coupling of hypervalent iodine diazo compounds with 2-arylpyridine borane complexes has been developed, enabling an efficient synthesis of diverse organoboron carboxylates in good to excellent yields with high chemoselectivity. Unlike traditional carbene B-H insertion reactions that form C-B bonds, this method proceeds via a borane-to-carbene hydride transfer pathway, providing a new strategy for organoboron carboxylate construction. The reaction shows broad substrate scope, good functional-group tolerance, and is scalable. Mechanistic studies support formation of a Pd-carbene intermediate followed by hydride transfer and rearrangement. Preliminary biological evaluation shows that selected products exhibit antiproliferative activity against multiple cancer cell lines, with compound 3m showing the highest potency (IC
Indexed as
Identifiers
42622744What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.